Product Code: 978-1-68038-736-0
Hemoglobinopathies Market Growth & Trends
The global hemoglobinopathies market size is expected to reach USD 15.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.8% from 2021 to 2028. Increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are expected to propel the market growth over the forecast period. Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.
The development of novel curative technologies, such as CRISPR/Cas9 and hematopoietic stem cell transplantation, coupled with a promising pipeline, is expected to propel market growth. Moreover, the presence of regulatory agencies, such as the FDA, which are working toward improving drug approval rate by granting accelerated approval for hemoglobinopathies drugs, is expected to drive the market. For instance, in 2019, the FDA has approved four novel drugs: Reblozyl by Bristol-Myers Squibb Company, Adakveo by Novartis AG, Zynteglo by bluebird bio, Inc., and Oxbryta by Global Blood Therapeutics, Inc. for the treatment of hemoglobinopathies.
Initiatives such as the Sickle Cell Awareness Initiative (SCAI) are working toward educating the people about the disease, which will increase the diagnosis and treatment rate. SCAI also raises funds for individuals affected with sickle cell diseases (SCDs) and provides research funding. Moreover, governments of Middle Eastern and Asian countries provide funds for R&D of hemoglobinopathies treatment. For instance, various programs undertaken by governments, such as thalassemia screening in neonates and providing medicines, are impacting the market growth positively.
The high patient population in low-income countries has encouraged market players and non-profit organizations to launch several initiatives to improve the access to the therapy. For instance, in February 2019, the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) was launched by Global Blood Therapeutics, Inc. in order to provide research funding for novel SCD projects, with an aim to expand the access to optimal healthcare for sickle cell disease.
Biopharmaceutical companies are collaborating with nonprofit organizations to promote public awareness about hemoglobinopathies. For instance, in June 2018, the Sickle Cell Disease Association of America partnered with Emmaus Life Sciences, Inc. to provide online educational tools to sickle cell patients, friends, clinicians, caregivers, and researchers for spreading awareness about complications associated with SCD.
An increase in investment and funding for the development of novel therapies to treat hemoglobinopathies will further boost the market growth over the forecast period. The National Heart, Lung, and Blood Institute (NHLBI) has significantly invested in research & development in sickle cell disease. The NHLBI supports research work through various initiatives. Furthermore, private funding such as the Bronx Blood Research Fund (BBRF) provides a platform for research and management of thalassemia and other hemoglobinopathies.
Gene therapy has emerged as a promising treatment option for managing hemoglobin disorder as it targets the underlying genetic cause of the condition through the administration of one-time gene therapy and significantly reduces the need for blood transfusions. The current pipeline of gene therapy products includes CTX001 (CRISPR Therapeutics), BIVV003 (Sangamo Therapeutics, Inc. & Bioverativ Inc), and HGB-206 (bluebird bio, Inc).
Hemoglobinopathies Market Report Highlights
- Based on type, sickle cell disease accounted for the largest share of 56.6% in 2020 and is anticipated to maintain its lead over the forecast period
- The newborn patient population with sickle cell anemia is anticipated to reach 400,000 by 2050. Half of the global sickle cell anemia burden is present in India, Nigeria, and the Democratic Republic of the Congo
- By therapy, in the thalassemia segment, the blood transfusion segment held the largest market share in 2020 and is estimated to dominate the market throughout the forecast period
- Asia Pacific is expected to witness the fastest growth over the forecast period owing to a large potential patient base and high unmet medical needs in the region
- North America held the largest market share in 2020 due to government initiatives focusing on the development of new therapies and better reimbursement scenario
Table of Contents
Chapter 1 Methodology and Scope
- 1.1 Market Segmentation
- 1.1.1 Estimates and Forecast Timeline
- 1.2 Research Methodology
- 1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 GVR's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details of Primary Research
- 1.4 Information or Data Analysis
- 1.4.1 Data Analysis Models
- 1.5 Market Formulation & Validation
- 1.6 Model Details
- 1.6.1 Commodity Flow Analysis
- 1.6.1.1 Approach 1: Commodity Flow Approach
- 1.6.1.2 Approach 2: Country-wise Market Estimation Using Bottom-Up Approach
- 1.7 Global Market: CAGR Calculation
- 1.8 Research Assumptions
- 1.9 List of Secondary Sources
- 1.10 Objectives
- 1.10.1 Objective 1:
- 1.10.2 Objective 2:
- 1.11 List of Abbreviations
Chapter 2 Executive Summary
Chapter 3 Global Hemoglobinopathies Market Variables, Trends & Scope
- 3.1 Penetration and Growth Prospect Mapping
- 3.2 Epidemiology Assessment of Hemoglobinopathies
- 3.2.1 Sickle cell disease
- 3.2.2 Thalassemia
- 3.3 Market Variable Analysis
- 3.3.1 Increasing prevalence of hemoglobinopathies in under-developed countries
- 3.3.2 High unmet needs
- 3.3.3 Increasing R&D investment
- 3.3.4 Initiatives to improve disease awareness levels
- 3.4 Market Restraint Analysis
- 3.4.1 Lack of healthcare infrastructure
- 3.4.2 High cost of treatment
- 3.5 SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
- 3.6 Porter's Five Forces Analysis
Chapter 4 Hemoglobinopathies Market - Segment Analysis, by Type, 2017 - 2028 (USD Million)
- 4.1 Market: Type Movement Analysis
- 4.2 Thalassemia
- 4.2.1 Market estimates and forecast, 2017 - 2028 (USD Million)
- 4.2.2 Alpha Thalassemia
- 4.2.3 Beta thalassemia
- 4.3 Sickle Cell Disease
- 4.3.1 Market estimates and forecast, 2017 - 2028 (USD Million)
- 4.4 Other Hemoglobin (Hb) Variants
- 4.4.1 Market estimates and forecast, 2017 - 2028 (USD Million)
Chapter 5 Hemoglobinopathies Market - Segment Analysis, by Diagnosis, 2017 - 2028 (USD Million)
- 5.1 Hemoglobinopathies Market: Diagnosis Movement Analysis
- 5.2 Thalassemia Diagnosis
- 5.2.1 Thalassemia diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
- 5.2.2 Blood Test
- 5.2.3 Genetic Test
- 5.2.4 Prenatal Genetic Test
- 5.2.5 Pre-implantation Genetic Diagnosis
- 5.2.6 Electrophoresis
- 5.2.7 Others
- 5.3 Sickle Cell Disease Diagnosis
- 5.3.1 Sickle cell disease diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
- 5.3.2 Blood Test
- 5.3.3 Genetic Test
- 5.3.4 Prenatal Genetic Test
- 5.3.5 Electrophoresis
- 5.3.6 Others
- 5.4 Other Hemoglobin (Hb) Variants Diagnosis
- 5.4.1 Other hemoglobin (Hb) variants diagnosis market estimates and forecast, 2017 - 2028 (USD Million)
- 5.4.2 Blood Test
- 5.4.3 Genetic Test
- 5.4.4 Prenatal Genetic Test
- 5.4.5 Electrophoresis
- 5.4.6 Others
Chapter 6 Hemoglobinopathies Market - Segment Analysis, by Therapy, 2017 - 2028 (USD Million)
- 6.1 Hemoglobinopathies Market: Therapy Movement Analysis
- 6.2 Thalassemia Therapy
- 6.2.1 Thalassemia therapy market estimates and forecast, 2017 - 2028 (USD Million)
- 6.2.2 Blood Transfusion
- 6.2.3 Iron Chelation Therapy
- 6.2.4 Bone Marrow Transplant
- 6.2.5 Others
- 6.3 Sickle Cell Disease Therapy
- 6.3.1 Sickle cell disease therapy market estimates and forecast, 2017 - 2028 (USD Million)
- 6.3.2 Blood Transfusion
- 6.3.3 Hydroxyurea
- 6.3.4 Bone Marrow Transplant
- 6.3.5 Others
- 6.4 Other Hemoglobin (Hb) Variants Therapy
- 6.4.1 Other hemoglobin (Hb) variants therapy market estimates and forecast, 2017 - 2028 (USD Million)
- 6.4.2 Blood Transfusion
- 6.4.3 Hydroxyurea
- 6.4.4 Iron Chelation Therapy
- 6.4.5 Bone Marrow Transplant
- 6.4.6 Others
Chapter 7 Hemoglobinopathies Market - Segment Analysis, by Region, 2017 - 2028 (USD Million)
- 7.1 Hemoglobinopathies Market: Regional Movement Analysis
- 7.2 North America
- 7.2.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
- 7.2.2 U.S.
- 7.2.2.1 U.S. market estimates and forecast, 2017 - 2028 (USD Million)
- 7.3 Canada
- 7.3.1.1 Canada market estimates and forecast, 2017 - 2028 (USD Million)
- 7.4 Europe
- 7.4.1 Europe market estimates and forecast, 2017 - 2028 (USD Million)
- 7.4.2 U.K.
- 7.4.2.1 U.K. market estimates and forecast, 2017 - 2028 (USD Million)
- 7.4.3 Germany
- 7.4.3.1 Germany market estimates and forecast, 2017 - 2028 (USD Million)
- 7.4.4 France
- 7.4.4.1 France market estimates and forecast, 2017 - 2028 (USD Million)
- 7.4.5 Italy
- 7.4.5.1 Italy market estimates and forecast, 2017 - 2028 (USD Million)
- 7.4.6 Spain
- 7.4.6.1 Spain market estimates and forecast, 2017 - 2028 (USD Million)
- 7.4.7 Russia
- 7.4.7.1 Russia market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5 Asia Pacific
- 7.5.1 Asia Pacific market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.2 Japan
- 7.5.2.1 Japan market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.3 China
- 7.5.3.1 China market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.4 India
- 7.5.4.1 India market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.5 South Korea
- 7.5.5.1 South Korea market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.6 Singapore
- 7.5.6.1 Singapore market estimates and forecast, 2017 - 2028 (USD Million)
- 7.5.7 Australia
- 7.5.7.1 Australia market estimates and forecast, 2017 - 2028 (USD Million)
- 7.6 Latin America
- 7.6.1 Latin America market estimates and forecast, 2017 - 2028 (USD Million)
- 7.6.2 Brazil
- 7.6.2.1 Brazil market estimates and forecast, 2017 - 2028 (USD Million)
- 7.6.3 Mexico
- 7.6.3.1 Mexico market estimates and forecast, 2017 - 2028 (USD Million)
- 7.6.4 Argentina
- 7.6.4.1 Argentina market estimates and forecast, 2017 - 2028 (USD Million)
- 7.7 Middle East & Africa
- 7.7.1 Middle East & Africa market estimates and forecast, 2017 - 2028 (USD Million)
- 7.7.2 South Africa
- 7.7.2.1 South Africa market estimates and forecast, 2017 - 2028 (USD Million)
- 7.7.3 United Arab Emirates
- 7.7.3.1 United Arab Emirates market estimates and forecast, 2017 - 2028 (USD Million)
- 7.7.4 Saudi Arabia
- 7.7.4.1 Saudi Arabia market estimates and forecast, 2017 - 2028 (USD Million)
Chapter 8 Competitive Analysis
- 8.1 Recent Developments & Impact Analysis, by Key Market Participants
- 8.1.1 Ansoff matrix
- 8.1.2 Company/Competition Categorization (Key innovators, Market leaders, Expansion)
- 8.1.3 Innovators
- 8.1.4 Market Leaders
- 8.2 Vendor Landscape
- 8.2.1 List of key distributors and channel partners
- 8.2.2 Key customers
- 8.2.3 Strategic framework
- 8.3 Major Deals and Strategic Alliances Analysis
- 8.3.1.1 New product launch
- 8.3.1.2 Mergers and acquisitions
- 8.3.1.3 Expansion
- 8.3.1.4 Partnerships
- 8.3.1.5 Marketing & promotions
- 8.4 Company Profiles
- 8.4.1 Sangamo Therapeutics
- 8.4.1.1 Company overview
- 8.4.1.2 Financial performance
- 8.4.1.3 Product benchmarking
- 8.4.1.4 Strategic initiatives
- 8.4.2 bluebird bio, Inc.
- 8.4.2.1 Company overview
- 8.4.2.2 Financial performance
- 8.4.2.3 Product benchmarking
- 8.4.2.4 Strategic initiatives
- 8.4.3 Global Blood Therapeutics, Inc.
- 8.4.3.1 Company overview
- 8.4.3.2 Financial performance
- 8.4.3.3 Product benchmarking
- 8.4.3.4 Strategic initiatives
- 8.4.4 Pfizer, Inc.
- 8.4.4.1 Company overview
- 8.4.4.2 Financial performance
- 8.4.4.3 Product benchmarking
- 8.4.4.4 Strategic initiatives
- 8.4.5 Emmaus Life Sciences, Inc.
- 8.4.5.1 Company overview
- 8.4.5.2 Financial performance
- 8.4.5.3 Product benchmarking
- 8.4.5.4 Strategic initiatives
- 8.4.6 Prolong Pharmaceuticals, LLC
- 8.4.6.1 Company overview
- 8.4.6.2 Product benchmarking
- 8.4.6.3 Strategic initiatives
- 8.4.7 Celgene Corporation (BMS)
- 8.4.7.1 Company overview
- 8.4.7.2 Financial performance
- 8.4.7.3 Product benchmarking
- 8.4.7.4 Strategic initiatives
- 8.4.8 Bioverativ Inc. (Sanofi)
- 8.4.8.1 Company overview
- 8.4.8.3 Product benchmarking
- 8.4.8.4 Strategic initiatives
- 8.4.9 Gamida Cell
- 8.4.9.1 Company overview
- 8.4.9.2 Financial performance
- 8.4.9.3 Product benchmarking
- 8.4.9.4 Strategic initiatives
- 8.4.10 Novartis AG
- 8.4.10.1 Company overview
- 8.4.10.2 Financial Performance
- 8.4.10.3 Product Benchmarking
- 8.4.10.4 Strategic initiatives